Over the course of the past year Halberd Corporation (OTC:HALB) has been one of the companies which has made considerable strides in the field of healthcare-related research and yesterday it made another announcement with regard to a milestone.
The company announced yesterday that the research team at Mississippi State University (MSU), had been successful in concluding the initial phase of the preclinical model for the purpose of establishing the baseline testing parameters and the endpoints for the company’s innovative nasal spray, for which a patent is pending. The nasal spray from Halberd is meant for eliminating the inevitable aftereffects that are brought about by Traumatic Brain Injury. It tackles those effects by directly attacking the associated antigens in the human body’s cerebrospinal fluid.
One of the more important updates from Halberd was that MSU was actually ahead of schedule and was now engaged in quantifying the testing parameters related to the 2nd and 3rd phases of the testing of the product. However, it was noted that the parameters for those phases of testing would be completed in the near term.
The innovative research that has been undertaken by the team at MSU involves the application and development of specific testing mechanisms to correlate the degree of head impact with the extent of the resultant head injury in human beings. Once the whole thing is quantified by MSU, the actual testing of the product would commence. It could well be one to keep an eye on over the coming months.